Alluric

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Alluric

Quick Facts

Property Description
Active ingredient Allopurinol
Form Oral tablet formulation
Pharmacological class Antihyperuricemic agent
Common purpose Reduction of uric acid synthesis
Origin Synthetic compound

What Type of Medicine is Alluric? (Identity and Classification)

Alluric is a prescription-only medication containing the active ingredient Allopurinol, which is classified as a synthetic compound and a structural purine analogue. Allopurinol belongs to the high-level pharmacological category of antihyperuricemic agents and is a cornerstone anti-gout agent. This designation means the drug's primary therapeutic role is centered on controlling chronic conditions involving the excessive production of uric acid, and it is clinically recognized for its effectiveness as a foundational treatment in managing long-term urate levels.


Allopurinol Composition and Formulation

The essential component of Alluric is the active ingredient Allopurinol, and it is primarily administered as an oral formulation supplied in tablets. This drug form uses the common oral route for administration. Allopurinol products are typically manufactured as a single-ingredient product, where the therapeutic activity stems solely from the Allopurinol compound. The tablets incorporate standard solid oral excipients—pharmaceutical inactive ingredients that ensure the physical integrity and stability of the medicine without contributing to the pharmacological effect.


The General Purpose of Alluric (Source Reduction)

The fundamental purpose of Alluric is to safely and sustainably manage and reduce unnaturally high levels of uric acid in the bloodstream, a metabolic state referred to as hyperuricemia. This goal is achieved because Allopurinol acts as a specific xanthine oxidase inhibitor, directly blocking the enzyme responsible for the creation of uric acid. By targeting this enzyme, Alluric provides the therapeutic benefit of limiting the synthesis of uric acid at its source, which is critical for long-term hyperuricemia control, such as when a patient requires sustained urate lowering to manage their condition.

Regulatory References

  1. MedlinePlus Drug Information: Allopurinol

What side effects are possible with Alluric?

Possible Side Effects and Safety Information

This section describes the safety characteristics and officially documented adverse reactions associated with Alluric (Aripiprazole) as categorized in regulatory documents.

Frequency-Classified Adverse Reactions

Adverse reactions are formally grouped by how frequently they are observed in clinical use. Those classified as Very Common (occurring in 1 in 10 patients or more) include Insomnia, Akathisia (a feeling of restlessness), and Headache. Common effects (occurring in 1 in 100 to less than 1 in 10 patients) include Somnolence, Extrapyramidal disorder, Tremor, and gastrointestinal issues like Nausea and Constipation.

These effects are organized by System-Organ Class, with effects heavily documented in the Nervous System and Gastrointestinal categories.


Serious and Population-Specific Safety Considerations

Official labeling documents several serious adverse reactions. These include the risk of Neuroleptic Malignant Syndrome (NMS), a potentially fatal condition, and the development of Tardive Dyskinesia (TD), a movement disorder. The medicine is also associated with Metabolic Changes, such as weight gain and dyslipidemia, and is linked to an increased risk of Suicidal Thoughts and Behaviors, particularly in younger adults during the initial few months of therapy or following dose changes.

For specific patient groups, the label carries safety constraints. The medication is explicitly not approved for use in elderly patients with dementia-related psychosis due to a documented increased risk of death and cerebrovascular events. Furthermore, caution is advised for patients with a history of seizures or cardiovascular conditions predisposing to Orthostatic Hypotension.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents specify that immediate medical attention is required upon known or suspected overdosage of Alluric (Aripiprazole). Management focuses exclusively on supportive care and rigorous medical supervision until the patient is fully recovered.

Documented Overdose Manifestations

Overdose cases documented in regulatory prescribing information commonly present with severe symptoms affecting the central nervous system, including marked somnolence (drowsiness), tremor, and a confusional state. Gastrointestinal manifestations such as vomiting are also listed, alongside more serious events like convulsions (seizures) and aggression.

Severe Outcomes and Monitoring Mandates

The official profile highlights the risk of severe, life-threatening outcomes, including coma and serious cardiovascular effects such as atrial fibrillation and a lowered heart rate, known as bradycardia. Due to these risks, an Electrocardiogram (ECG) must be obtained immediately. Continuous cardiac monitoring is mandated if any cardiac abnormalities, such as QT interval prolongation, are detected.

Emergency Actions and Supportive Measures

The regulatory basis for treatment is purely symptomatic, as no specific antidote is known for Aripiprazole overdosage. Procedural measures for managing the clinical state include maintaining a clear airway and potentially utilizing early administration of activated charcoal or gastric lavage for decontamination. Overdosage has been reported in children (age 12 and younger) and has been associated with fatalities, particularly in combined ingestions.

Therapeutic Uses of Alluric

Alluric (aripiprazole) is an atypical antipsychotic that is commonly used to help with a range of psychiatric conditions characterized by episodic or fluctuating manifestations. The main therapeutic areas of use include managing schizophrenia and easing acute manic and mixed episodes associated with Bipolar I Disorder. The medicine is also used when supportive symptom management is appropriate for Major Depressive Disorder (MDD). Furthermore, Alluric is relevant for easing symptom clusters that create noticeable functional strain, specifically irritability associated with Autistic Disorder and the motor or vocal symptoms of Tourette's Disorder. These conditions involve symptoms related to heightened physiological activity that require symptomatic assistance. Overall, it offers symptomatic relief and helps maintain a sense of stability when symptoms are more noticeable. This supports the patient during difficult episodes by easing distress. The medication may assist with maintaining functional stability during episodes of heightened discomfort.

Quick Fact: Relevant for symptoms that interfere with daily functioning

Eligibility and Restrictions for Use

Alluric's eligibility is determined by specific population restrictions documented in regulatory labeling from government agencies. The medicine has formal prohibitions and defined limits based on age and clinical status.

Populations Contraindicated from Use

Use is strictly prohibited for any patient with a known hypersensitivity to aripiprazole or any component of the drug. Additionally, the drug is contraindicated for use in elderly patients being treated for psychosis associated with dementia, as specified by the FDA Boxed Warning.

Age-Group and Condition Restrictions

Eligibility varies by age and indication. The drug is approved for pediatric use (age ge 6 years) for Tourette’s Disorder and Irritability associated with Autistic Disorder. Its safety and efficacy have not been established in patients aged 65 years and older for Schizophrenia or Bipolar I Disorder (EMA). Use requires caution in patients with a history of seizures or known cardiovascular or cerebrovascular disease.

Special Status Considerations

For patients with severe hepatic impairment, data are insufficient to establish dosing recommendations. Use during the third trimester of pregnancy may result in neonatal extrapyramidal and/or withdrawal symptoms; for nursing mothers, the decision to continue the drug or discontinue nursing must be made.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Alluric (Allopurinol) is defined by its role as a xanthine oxidase inhibitor, impacting the clearance of specific co-administered medications. Co-administration of Didanosine, Pegloticase, and Capecitabine is formally classified as contraindicated in regulatory labeling due to the risk of severe toxicity or reduced efficacy. A major consequence of enzyme inhibition is the significant reduction in clearance for Mercaptopurine and its prodrug Azathioprine, a documented interaction that necessitates a mandatory reduction of the concomitant medicine’s dosage. The metabolism of Theophylline is also inhibited, leading to increased plasma concentrations.

Other interactions involve pharmacodynamic risk reinforcement or exposure modification. Concurrent use with certain cytotoxic agents (like Cyclophosphamide) may increase the incidence of bone marrow suppression. Co-administration with Ampicillin or Amoxicillin is associated with an increased incidence of skin rash. Allopurinol may also potentiate the effect of Warfarin and increase the plasma levels of Cyclosporine.

Specific administration rules exist for Aluminum Hydroxide antacids, which must be administered with a separation of at least three hours to prevent impaired absorption of Allopurinol. Furthermore, the risk of serious interaction-related toxicity, such as hypersensitivity reactions with Thiazide diuretics, is officially noted to be heightened in patients with pre-existing impaired renal function.

Mechanism of Action

Primary Mechanism: Source Reduction via Enzyme Inhibition

Alluric's core action is the sustained inhibition of the enzyme Xanthine Oxidase (XO), a pivotal component of the purine catabolism pathway. The drug, and its long-acting metabolite, Oxypurinol, directly halt the conversion of purine precursors (hypoxanthine and xanthine) into uric acid. This molecular action establishes a metabolic constraint that immediately reduces the body’s overall synthesis of uric acid.


Physiological Consequence: Crystal Dissolution

The resulting sustained reduction of circulating uric acid concentration, a direct physiological effect of XO inhibition, forces the plasma level below the saturation point necessary to maintain crystal stability. This shift in the physical-chemical environment drives a concentration gradient, which, over time, promotes the dissolution of pre-existing Monosodium Urate (MSU) crystal deposits in tissues.


Mechanistic Limitation: Lack of Acute Pathway Modulation

This mechanism is strictly focused on chronic metabolic source reduction and crystal dissolution. Since it does not interact with the pathways of acute pain signaling or inflammatory mediators (e.g., prostaglandins, cytokines), it does not modulate the biological cascades required for the resolution of acute inflammation.

Dosage and Administration Information

How Alluric is Used: Official Administration Guidelines

Alluric (Allopurinol) is administered through two official routes: the oral route via tablets and the intravenous (IV) infusion route using a powder for injection. The specific method of use is structured to ensure precise dosing and intake conditions, primarily focusing on chronic conditions and prophylaxis.


Official Dosing and Administration

Feature Guideline
Starting Dose Typically 100 mg orally once daily for chronic management. Lower starting doses, such as 50 mg daily, are required for patients with impaired kidney function.
Dosing Pattern The dose must be titrated (gradually adjusted), generally in increments of 100 mg at appropriate intervals (e.g., weekly), until the target serum urate level is achieved.
Maximum Dose The maximum recommended daily oral dose is 800 mg.
Frequency Doses up to 300 mg may be taken once daily. Oral doses exceeding 300 mg must be given in divided doses to minimize gastrointestinal intolerance.

Administration Conditions and Special Rules

  • Intake Condition: Oral tablets should be taken after a meal to reduce the risk of gastric irritation. Maintaining a high daily fluid intake is also recommended.
  • Dose Adjustment: Significant dose reductions are mandatory for patients with renal impairment, as the drug is primarily cleared by the kidneys.
  • Prophylactic Timing: When used to prevent hyperuricemia caused by cancer therapy, administration must be initiated 24 to 48 hours before the start of chemotherapy.
  • Missed Dose: If an oral dose is missed, it should not be doubled at the next scheduled time; the patient should simply resume the regular dosing schedule.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Alluric (Allopurinol)

Evidence for Use in Chronic Gout Management

Research on Alluric's use for chronic gout management is extensive, relying primarily on Randomized Controlled Trials (RCTs) and long-term comparative studies. These studies were designed to explore the long-term changes in uric acid levels for adults diagnosed with gout, including those with advanced symptoms like tophaceous deposits. Researchers monitored outcomes related to the body's physiological balance, specifically tracking the proportion of participants who reached a specific target goal for serum urate (sUA) levels over time.

Studies examined the severity and frequency of gout flares in the observed populations. In this research context, findings describe patterns observed in flare incidence during the study period. Research suggests that sUA target levels were not always reached in routine care, which studies associate with a pattern of suboptimal dosing outside of a controlled trial.


Evidence for Use in Preventing Tumor Lysis Syndrome (TLS)

Alluric was studied for use in the acute clinical situation known as Tumor Lysis Syndrome (TLS), a condition involving temporary physiological imbalance that can occur during cancer treatment. The research primarily consisted of acute-setting studies. These studies were conducted during periods of increased symptom activity, specifically before and after the start of chemotherapy for malignancies.

Studies monitored outcomes reflecting physiological strain, focusing on the changes observed in serum and urinary uric acid levels. Research also examined outcomes related to acute kidney injury. Findings describe the agent’s role in inhibiting the enzyme responsible for uric acid creation during the period of high cell turnover. While studies have included both adult and pediatric patients, most of the data collected is focused strictly on the short period of acute risk following chemotherapy.


Research Gaps and Areas of Uncertainty

Research provides context on what has been observed so far, but like all medicines, there are areas where data are still emerging. Follow-up durations were limited in some of the smaller studies. Evidence quality varies across studies, and some older trials employed modest sample sizes. Research also describes a persistent tension between results achieved in highly controlled trial environments and the patterns observed in routine care.

Key Studies & References

  1. NICE Clinical Guideline [CG176]: Gout: diagnosis and management
  2. Systematic Review of Allopurinol in Prevention of Calcium Oxalate Nephrolithiasis

Frequently Asked Questions (FAQ)

Common questions about Alluric (FAQ)

Q: Is it normal to feel tired when starting Alluric?

Official information indicates that Alluric (Allopurinol) has been associated with central nervous system effects, including drowsiness and somnolence (sleepiness). As this is a documented side effect, it is not unusual to experience feelings of fatigue, especially when starting the medication.

Q: Are there any long-term side effects of taking Alluric that I should know about?

Regulatory documents note that there is a risk of serious, though rare, reactions that may occur, sometimes after long periods of use. These include the potential for reversible hepatotoxicity (liver injury) and myelosuppression (bone marrow suppression), which can affect the body’s ability to produce blood cells. Monitoring by a healthcare provider may be necessary during long-term therapy to check for these effects.

Q: How quickly does Alluric start to work?

The medication is rapidly converted in the body to its long-acting therapeutic component. While this conversion happens quickly, the therapeutic goal of achieving a sustained reduction of uric acid in the blood may take a period of several weeks to months as the dose is adjusted.

Q: Where can I find the official regulatory information about Alluric?

Complete, official drug information and regulatory labeling for the active ingredient, Allopurinol, is made available by government health agencies. These documents can typically be found on websites maintained by authorities such as the FDA DailyMed in the United States or the EMA Summary of Product Characteristics for European markets.

Q: Is there a generic version of Alluric available?

Yes, the active ingredient contained in Alluric is Allopurinol. Allopurinol is a widely prescribed compound and is available in many regions as a generic prescription product from various manufacturers.

Q: Does Alluric affect my ability to drive or operate machinery?

Because Allopurinol may cause drowsiness or somnolence (sleepiness), regulatory labeling advises caution regarding driving or operating machinery until it is known how the medication affects an individual. This is to ensure patient safety while performing tasks that require concentration.

Q: Can Alluric make me feel dizzy?

Official labeling notes that the drug may cause effects like drowsiness and somnolence. The medication may also be associated with orthostatic hypotension (a drop in blood pressure when standing up), which can sometimes lead to sensations of lightheadedness or dizziness.

Q: What foods should I avoid while taking Alluric?

Regulatory guidance on Allopurinol focuses on administration, recommending that the tablets be taken after a meal to help reduce stomach irritation. It is also advised that patients maintain a high daily fluid intake. No specific foods are generally prohibited in official regulatory labeling.

Q: What is the purpose of the different strengths or forms of Alluric?

Allopurinol is available in oral tablets and an intravenous (IV) form. The oral tablets are typically used for long-term management and are available in different strengths to allow for dose titration (adjustment). The IV form is generally reserved for acute clinical situations requiring rapid action, such as preventing Tumor Lysis Syndrome.

Q: Does Alluric weaken my immune system?

Alluric is not formally classified as a drug that suppresses the immune system. However, official information notes that the drug has, in rare cases, been associated with bone marrow suppression (myelosuppression). Official information notes that a concurrent use with other medications that affect the bone marrow may be associated with increased risk.

Q: Can I take Alluric if I have diabetes or high blood pressure?

Regulatory information advises caution for patients with a history of cardiovascular conditions (like high blood pressure) and notes potential for metabolic changes (relevant to diabetes). For individuals with these conditions, close monitoring by a healthcare provider is generally recommended during treatment.

Q: Does Alluric interact with common pain relievers like Tylenol or Advil?

Official information generally suggests that Allopurinol can be used alongside common non-prescription pain relievers like acetaminophen (Tylenol) or NSAIDs such as ibuprofen (Advil). Given the complexity of drug combinations, it is important to discuss all combinations of medications with a healthcare provider.

Q: Should I worry about mixing Alluric with herbal supplements?

There is a general lack of testing and formal regulatory data regarding interactions between prescription medications and most herbal remedies, vitamins, and supplements. Because the potential for unknown interactions exists, it is important to discuss all supplements with a healthcare provider.

Q: Can I drink alcohol while using Alluric, and what are the general warnings?

Official regulatory warnings state that consuming alcohol may increase the risk of specific nervous system side effects associated with the drug, particularly drowsiness. The decision to limit or avoid consumption should be discussed with a healthcare provider.

Q: Will I need regular blood tests while taking Alluric?

Yes, official regulatory guidance indicates that blood and urine tests are often needed. These tests are conducted at regular intervals to allow the healthcare provider to monitor the body's response, specifically checking uric acid levels, kidney function, and liver function.

Q: Is it safe to get vaccines while taking Alluric?

Some medical guidance advises that starting Allopurinol treatment should generally not occur within two weeks of a viral infection or a vaccination. This caution is generally noted to help ensure that any adverse reactions are correctly attributed.

Q: What is the half-life of Alluric? (High-level explanation)

The term half-life describes the time it takes for half of the drug to be eliminated from the body. The active component of Alluric, Oxypurinol, has a relatively long half-life of approximately 23 hours in people with normal kidney function, which contributes to the medication’s once-daily dosing potential.

Q: Is the active ingredient in Alluric a common one?

Yes, the active ingredient, Allopurinol, is a very well-known and foundational medication. It is officially classified as the most frequently prescribed urate-lowering agent and is considered a cornerstone treatment for managing chronic high uric acid levels.

Q: How does the drug stay in my system?

Alluric is quickly converted into its long-acting active metabolite, called Oxypurinol. This metabolite has a long half-life and is primarily removed from the body by the kidneys. This process of gradual kidney clearance is why the drug maintains its therapeutic effect in the body over an extended period.

Q: Are there any restrictions on sun exposure while using Alluric?

While it is not a common warning, there are occasional post-marketing reports of photosensitivity (increased sensitivity to sunlight) associated with this drug class. Official information may advise caution with sun exposure to help prevent a possible skin reaction.

Q: What should I do if the side effects of Alluric bother me?

Regulatory documents state that a healthcare provider should be contacted if side effects are severe, persistent, or do not go away. Immediate emergency medical attention is necessary if signs of a serious reaction, such as a severe rash or difficulty breathing, occur.

Q: How does Alluric affect liver function?

Official documentation notes that Allopurinol may cause hepatotoxicity, which is injury to the liver. Regulatory text advises that if a patient develops signs of liver problems, their liver function should be thoroughly evaluated, and guidance from a healthcare provider may be required regarding continuation of the medication.

Q: Is it common for people to take Alluric with other medications for the same condition?

Yes, official guidance often notes that Allopurinol may be prescribed concurrently with other medications, such as a colchicine or a non-steroidal anti-inflammatory drug (NSAID). This is often done during the beginning of treatment to help prevent acute flares while the long-term uric acid levels are being lowered.

Q: Can Alluric cause hair loss?

Hair loss or thinning of the hair (alopecia) has been reported as a rare effect in post-marketing surveillance and clinical studies of the active ingredient. While rare, it is a documented finding associated with the drug.

Q: What if I take too much Alluric by accident?

Regulatory guidance notes the importance of seeking medical attention, such as calling a poison control center or emergency services, immediately if an overdose is suspected. This ensures appropriate medical intervention can be provided promptly.

How should Alluric be stored and disposed of?

How to Store and Dispose of Alluric?

The official labeling for Alluric (allopurinol) tablets defines specific conditions for storage and disposal to maintain product quality and safety.


Storage Requirements

The medication must be stored at USP Controlled Room Temperature, specifically between 20 and 25C (68 to 77F). It is mandatory to store the tablets in a dry place with the container tightly closed to protect it from moisture. As a safety measure, Alluric must be kept out of the reach of children.


Disposal Instructions

Unused or expired Alluric must be disposed of according to local regulations. Regulatory guidance instructs patients to follow proper disposal procedures, such as Drug Take Back Day programs or authorized collection sites, to ensure the medicine is discarded safely.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Alluric found in:

A-Z Index: